Subjective Responses to Alcohol Consumption as Endophenotypes: Advancing Behavioral Genetics in Etiological and Treatment Models of Alcoholism

LARA A. RAY,1 JAMES MACKILLOP2 AND PETER M. MONTI3

1Department of Psychology, University of California, Los Angeles, California, USA
2Department of Psychology, University of Georgia, Athens, Georgia, USA
3Providence Veterans Affairs Medical Center and Center for Alcohol and Addiction Studies, Brown University, Providence, Rhode Island, USA

Individual differences in subjective responses to alcohol consumption represent genetically mediated biobehavioral mechanisms of alcoholism risk (i.e., endophenotype). The objective of this review is three-fold: (1) to provide a critical review the literature on subjective response to alcohol and to discuss the rationale for its conceptualization as an endophenotype for alcoholism; (2) to examine the literature on the neurobiological substrates and associated genetic factors subserving individual differences in subjective response to alcohol; and (3) to discuss the treatment implications of this approach and to propose a framework for conceptualizing, and systematically integrating, endophenotypes into alcoholism treatment.

Keywords alcohol; subjective responses; endophenotypes; genetics; pharmacogenetics; behavioral marker; craving; alcoholism

Introduction

Alcohol is a commonly used addictive substance with multiple behavioral and neurobiological effects. As a psychoactive compound, it can elicit a spectrum of behavioral effects, which include gregariousness, anxiolysis, aggression, loss of executive functions and cognitive deficits. A host of pharmacokinetic factors (i.e., absorption, distribution in the tissues, and rate of metabolism—primarily in the liver) contribute to the intensity and duration of ethanol’s effects, whereas an array of pharmacodynamic factors, determine the behavioral and subjective effects of ethanol on the brain. The spectrum of subjective responses to alcohol is attributed to the ability of ethanol to inhibit or to activate multiple neural pathways. Specifically, how a person responds to alcohol will ultimately depend on how the neural pathways are organized in that individual and the extent to which certain pathways are inhibited or activated. It is well known that there is substantial variability in the subjective

LAR was supported by a grant (T32 AA007459) from the National Institute on Alcohol Abuse and Alcoholism.

Address correspondence to Lara A. Ray, Ph.D., Assistant Professor, Psychology Department, University of California, Los Angeles, 1285 Franz Hall, Box 951563, Los Angeles, CA 90095-1563; E-mail: lararay@psych.ucla.edu.
response to alcohol and that differences in the subjective experiences of ethanol’s effects appear to play a significant role in the predisposition to alcohol abuse\(^1\) and dependence (e.g., Schuckit and Smith, 1996; Schuckit, Tsuang, Anthenelli, Tipp, and Nurnberger, 1996).

In light of the significance of subjective response to alcohol as a putative biobehavioral marker of alcoholism risk,\(^2\) the objective of this manuscript is three-fold. First is to provide a critical review the empirical literature on subjective response to alcohol and to discuss the rationale for its conceptualization as an endophenotype for alcoholism. Second is to examine the literature on the neurobiological substrates and associated genetic factors subserving individual differences in subjective response to alcohol. This will be done by systematically considering two important pharmacological processes relevant to alcohol’s biobehavioral effects, namely pharmacokinetics and pharmacodynamics. Third is to discuss the treatment implications of considering subjective responses to alcohol as endophenotypes and to propose a framework for conceptualizing and systematically integrating endophenotypes into treatment approaches for alcoholism. Finally, limitations and future directions will be discussed.

**Subjective Responses to Alcohol as Endophenotypes**

**Subjective Responses to Alcohol**

Individuals vary widely in their subjective experience of the pharmacological and neurobehavioral effects of alcohol upon its consumption. Pharmacological effects focus on the cellular and physiological effects of alcohol while subjective experiences focus on an individual’s self-reported perceptions of the effects of the substance. While some individuals may be more or less sensitive to the positively reinforcing and stimulant effects of alcohol, others report higher sensitivity to the aversive sedative effects. Recent research, primarily from alcohol administration studies, has documented the substantial variability in individuals’ subjective responses to alcohol and has shown that differences in these subjective experiences may play a significant role in the predisposition to alcohol use and misuse (e.g., Schuckit and Smith, 1996). Importantly, recent studies have shown that subjective response to alcohol represents a heritable phenotype (Heath and Martin, 1991; Viken, Rose, Morzorati, Christian, and Li, 2003).

So what constructs encompass subjective responses to alcohol? Schuckit and colleagues produced the early seminal work on the assessment of self-reported subjective response to alcohol by measuring self-reported subjective intoxication during alcohol administration sessions (i.e., alcohol challenge) (e.g., Schuckit, 1980). In the context of Schuckit’s work, the primary measure of subjective responses to alcohol is the Subjective High Assessment Scale (SHAS). The SHAS consists of various positive and negative mood-related adjectives, in addition to a single item ad hoc scale of “feeling high.” Principal components analysis of the SHAS suggested that the “maximum terrible feelings” construct loaded into a first factor and accounted for 46% of the total variance (Schuckit, 1985), thereby suggesting that the SHAS may be most sensitive to the unpleasant effects of alcohol. Perhaps the most compelling evidence that subjective responses to alcohol predict alcohol use and misuse comes from a longitudinal study of sons of alcohol dependent probands and controls, suggesting that individuals who demonstrated low response to alcohol in the laboratory

---

\(^1\)The journal’s style utilizes the category *substance abuse* as a diagnostic category. Substances are used or misused; living organisms are and can be *abused*. Editor’s note.

\(^2\)Risk is hereby defined as the predisposition to developing alcoholism under certain environmental conditions, such as alcohol exposure.
(measured by the SHAS) were significantly more likely to develop alcoholism at 8-year follow-up (Schuckit and Smith, 1996).

More recent work has suggested that alcohol’s pharmacological effects may be biphasic in nature (Earleywine, 1994a, 1994b; Earleywine and Martin, 1993; Erblich, Earleywine, Erblich, and Bovbjerg, 2003; Martin, Earleywine, Musty, Perrine, and Swift, 1993). Specifically, it has been documented that when blood alcohol levels are rising (i.e., the ascending limb of intoxication), alcohol produces robust stimulatory and other pleasurable subjective effects (Earleywine and Martin, 1993; Erblich et al., 2003). Conversely, when blood alcohol levels are declining (i.e., the descending limb of intoxication), alcohol’s effects are largely sedative and unpleasant (Earleywine and Martin, 1993; Erblich et al., 2003). This conceptualization of the effects of alcohol argues for the construct of subjective responses to be further parsed out into stimulant and sedative effects. Indeed, the Biphasic Alcohol Effects Scale (BAES; Earleywine and Martin, 1993) has been developed to directly assess the stimulant and sedative aspects of intoxication in alcohol administration studies. When subjective responses to alcohol are divided into stimulant and sedative effects, studies have shown that greater alcohol-induced stimulation and reinforcement is associated with increased alcohol consumption (Lewis and June, 1990; Wise and Bozarth, 1987), whereas greater subjective experiences of the sedative and unpleasant effects of alcohol are associated with decreased alcohol use (Leigh, 1987; O’Malley and Maisto, 1984).

In addition to the measures described above, various measures of mood states have been used in alcohol administration studies in order to capture the “mood-altering” effects of alcohol. Some of the most widely used measures of mood include the Profile of Mood States (POMS; McNair, Lorr, and Droppleman, 1971) and the Positive and Negative Affect Schedule (PANAS; Watson, Clark, and Tellegen, 1988). Although the concurrent use of these multiple measures provides more comprehensive assessment of individual differences in the subjective experience of alcohol consumption, they also raise issues regarding the core construct(s) of subjective responses to alcohol and how to best define it (them). Moreover, the multiple assessments of subjective intoxication further complicate the integration of findings in the alcohol administration literature.

In very global terms, the subjective effects of alcohol can be conceptualized in two broad domains, namely reinforcing (positively and negative) and punishing (aversive). However, these effects are not necessarily orthogonal to one another and may be concomitantly experienced to varying degrees within a single drinking episode. In order to empirically address the interrelationships among assessments of subjective intoxication used in alcohol administration studies, Table 1 presents previously unpublished data on the correlations among the SHAS, BAES, POMS, and urge to drink (measured by the Alcohol Urge Questionnaire; AUQ, Bohn, Krahn, and Staehler, 1995; MacKillop, 2006). These assessments were administered in the context of an intravenous alcohol administration study ($n = 49; 23$ women) of hazardous college drinkers. Pearson product-moment correlations are presented for the assessment point in which the target Breath Alcohol Concentration (BrAC) was 0.06 (for details see Ray, McGearly, Marshall, and Hutchison, 2006b).

Results of these correlational analyses indicate that the SHAS is most strongly correlated with the sedative effects of alcohol (BAES, sedation), although it is also moderately correlated with alcohol-induced stimulation (BAES, stimulation), which is in turn consistent with the notion that the SHAS contains both positive and negative adjectives related to alcohol’s subjective effects. Conversely, the BAES stimulation subscale was most strongly associated with vigor and positive mood, whereas its association with the sedation subscale was small and nonsignificant. Interestingly, the BAES stimulation subscale was the strongest predictor of urge to drink alcohol, accounting for approximately 36% of the
variance in self-reported urge. Similar relationships among these assessments of the subjective effects of alcohol were recently reported in an independent sample of hazardous drinkers (Ray, Meskew-Stacer, and Hutchison, 2007a) and in previous studies where indexes of vigor and physiological reactivity were inversely related to SHAS scores (Conrod, Peterson, and Pihl, 2001). Taken together, these findings highlight the need for further research on the optimal conceptualization and assessment of the construct of subjective responses to alcohol. Such research is critical in order to advance the field by increasing consistency comparability in the findings of alcohol administration studies, whether they focus on biobehavioral factors or underlying genetic risk for alcohol use disorders.

An important effort towards resolving discrepancies in the alcohol administration literature comes from the work of Newlin and Thompson (1990). In the context of their review of alcohol challenge studies of sons of alcohol dependent parents and controls, they proposed the influential differentiator model for understanding psychobiological responses to alcohol as a function of family history. This model can be applied more broadly, to conceptualizing individual differences in responses to alcohol. Newlin and Thompson’s (1990) differentiator model proposes that responses to alcohol may be accentuated during the rising blood alcohol curve (BAC) (i.e., acute sensitization) and attenuated during the falling BAC (i.e., acute tolerance). The authors propose that sons of alcohol dependent individuals may be both more sensitive to the rewarding effects of alcohol during the rising limb of the BAC and less sensitive to the unpleasant effects of alcohol when BAC is dropping. Importantly, acute tolerance and acute sensitization occur within session and represent a useful way to capture the “snap shot” of alcohol’s effects obtained in a single administration session. This model has influenced efforts to parse out the phenotype of subjective responses to alcohol as endophenotypes.

### Table 1

Correlations among measures of subjective responses to alcohol during the ascending limb of the breath alcohol concentration (BrAC = 0.06)

<table>
<thead>
<tr>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. SHAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. BAES Stimulation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. BAES Sedation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. POMS Vigor</td>
<td>0.03</td>
<td>0.72***</td>
<td>−0.14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. POMS Tension</td>
<td>0.14</td>
<td>−0.02</td>
<td>0.12</td>
<td>−0.10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. POMS Neg Mood</td>
<td>−0.04</td>
<td>−0.27</td>
<td>0.21</td>
<td>−0.29*</td>
<td>0.48***</td>
<td></td>
</tr>
<tr>
<td>7. POMS Pos Mood</td>
<td>0.29*</td>
<td>0.61***</td>
<td>0.13</td>
<td>0.63***</td>
<td>−0.32*</td>
<td>−0.43**</td>
</tr>
<tr>
<td>8. AUQ Urge to drink</td>
<td>0.43**</td>
<td>0.59***</td>
<td>0.15</td>
<td>0.41**</td>
<td>−0.06</td>
<td>−0.20</td>
</tr>
</tbody>
</table>

**Note:** Previously unpublished data from Ray, McGeary, Marshall, and Hutchison (2006); n = 49. **SHAS:** Subjective High Assessment Scale; **BAES:** Biphasic Alcohol Effects Scale (Subscale: Stimulation and Sedation); **POMS:** Profile of Mood States, Short Version (Subscales: Vigor, Tension, Negative and Positive Mood); **AUQ:** Alcohol Urge Questionnaire. * p < .05; ** p < .01; *** p < .001.
subjective response to alcohol into rewarding (primarily during the rising limb of BAC) and unpleasant (most salient during the descending limb of BAC).

This approach is somewhat consistent with the psychomotor stimulant theory of addictions which posits that the stimulatory and rewarding effects of addictive substances, including alcohol, share a common underlying biological mechanism and that individuals who experience greater alcohol-induced reward are thought to be more likely to develop alcohol problems (Wise and Bozarth, 1987). However, just as alcoholism represents a heterogeneous disorder (discussed in more detail below), family history of alcoholism constitutes a heterogeneous, and rather crude, measure of genetic risk. Newlin and Thompson (1990) note the role of pharmacokinetics and neurobiological and genetic differences, primarily via family history of alcoholism, underlying variation in response to alcohol. Recent developments in the understanding of both the genetic underpinnings of pharmacokinetic and pharmacodynamic processes underlying subjective responses to alcohol will be reviewed herein.

In summary, subjective responses to alcohol represent an important phenotype for alcohol use and misuse. Research evidence suggests that the way in which individuals’ experience the pharmacological effects of alcohol influences their subsequent use of alcohol (e.g., Lewis and June, 1990; Wise and Bozarth, 1987) and the risk of developing an alcohol use disorder (Schuckit and Smith, 1996). Moreover, subjective responses to alcohol are heritable (Heath and Martin, 1991; Viken et al., 2003) and informative regarding the neuropharmacological effects of alcohol and their biological and genetic bases. The differentiator model of response to alcohol (Newlin and Thompson, 1990) has been influential in distinguishing two related and biologically mediated processes that emerge during a single alcohol administration session, namely acute tolerance and acute sensitization. In the next sections, we will first introduce the concept of endophenotypes in psychiatric research and then discuss the conceptualization of subjective responses to alcohol as an endophenotype for alcoholism.

**Endophenotypes**

Behavioral and clinical scientists are largely interested in the behavioral manifestation of a given disorder, which can be thought of as a phenotype. The behavioral phenotypes used in many of the association studies, mostly consisting of diagnostic phenotypes such as alcohol abuse or dependence, are influenced by many different genetic as well as environmental factors. Because there are so many different factors that influence whether an individual receives a diagnosis of alcohol abuse or dependence, it has become increasingly important to identify more specific and narrowly defined behavioral phenotypes (i.e., intermediate phenotypes or “endophenotypes”) that are related to the larger disorder. Endophenotypes are thought to facilitate research in the neurobiology of psychiatric disorders by being more homogenous and narrowly defined than the larger diagnostic phenotype (Gottesman and Gould, 2003). Recent research in behavioral genetics has focused on identifying specific genes underlying individual differences in the vulnerability for the development of an alcohol use disorder. In light of such efforts, the identification of more narrow behavioral phenotypes, or endophenotypes, for alcoholism has received increased attention (e.g., Hines, Ray, Hutchison, and Tabakoff, 2005), as is the case for most psychiatric disorders (Burmeister, 1999; Gottesman and Gould, 2003). A good endophenotype should be narrowly defined, readily identifiable, and related to the disorder of interest (Hutchison, McGaery, Smolen, Bryan, and Swift, 2002). When used correctly, endophenotypes for
psychiatric disorders are expected to increase the power to detect specific genes underlying the risk for a given disorder.

In the abovementioned critical review of alcohol administration studies, Newlin and Thompson (1990) described psychobiological markers as characteristics, other than disease symptoms, that identify individuals who are most likely to develop a specific disorder. Importantly, psychobiological markers should be distinguished from the manifestation of prolonged drinking and there may be multiple psychobiological markers for alcoholism given that this disorder is likely to have a multidimensional etiology. The description of psychobiological markers by Newlin and Thompson (1990) and their putative utility in advancing alcoholism research closely resembles the concept of endophenotypes, as described in the psychiatric literature (Burmeister, 1999; Gottesman and Gould, 2003). A recent review of endophenotypes for alcoholism (Hines et al., 2005), suggested a number of candidate endophenotypes, such as behavioral and physiological traits (e.g., subjective responses to alcohol, alcohol metabolism, alcohol craving, and electrophysiological measures) and biochemical traits (e.g., monoamine oxidase and $\beta$-endorphins). The next section will review the conceptual framework and empirical data suggesting that subjective responses to alcohol constitute useful endophenotypes for alcoholism.

**Subjective Responses to Alcohol as Endophenotypes**

It is important to systematically evaluate phenotypes in order to determine whether or not they constitute an adequate, and potentially useful, endophenotype for the disorder of interest. Tsuang, Faraone, and Lyons (1993) have put forth specific criteria for evaluating endophenotypes. In this section, subjective responses to alcohol will be reviewed in light of their a-priori criteria: (1) specificity; (2) state-independence; (3) heritability; (4) familial association; (5) cosegregation; and (6) biological and clinical plausibility.

**Specificity** refers to the expectation that the endophenotype is more strongly associated with the disease of interest than to other psychiatric disorders. Given that subjective responses to alcohol are directly dependent upon alcohol consumption and its associated pharmacological effects, the argument can also be made that this phenotype is highly specific to the disorder of interest. However, the argument can be made that similar mechanisms of pharmacological response may be in play for substances other than alcohol, which in turn would argue for it being a broader phenotype for substance use disorders. Patterns of cross-tolerance between alcohol and benzodiazepines, for example, have been widely documented in the animal and human literature (e.g., Toki, Saito, Nabeshima, Hatta, Watanabe, and Takahata, 1996). Moreover, common neurotransmitter systems and pathways are involved in the reinforcing effects of multiple substances, as is the case for the dopaminergic and opioidergic systems, for example (Bond et al., 1998; Herz, 1997; Wise and Bozarth, 1987). In summary, responses to alcohol may be an alcohol-specific phenotype, although future research is needed to determine its specificity in relation to other substances of abuse and their common reward pathways, which in turn could help explain the high comorbidity between alcohol use disorders and other substance use disorders.

**State-independence** refers to the phenotype being stable and not simply a reflection of the disease process. As discussed above, the work of Schuckit and colleagues found that subjective responses to alcohol measured in the laboratory before the development of alcohol-related problems predict the development of alcohol use disorders at 8-year follow-up (Schuckit and Smith, 1996). That is true of even in the case of individuals who were relatively alcohol-naïve at the time of the alcohol challenge. Significantly less is known about the state-independence of alcohol’s reinforcing effects and its association to
alcohol use disorders. **Heritability** is an important criterion for evaluating endophenotypes and represents the degree to which the phenotype is influenced by genetic variance. Ideal endophenotypes are heritable and one would wish for a highly heritable endophenotype very much in the same way we expect our behavioral measures to be reliable, so as to reduce “noise.” Subjective responses to alcohol, measured in an experimental twin study, had a heritability estimate of 60% (Viken et al., 2003). This study used a 22-item measure called Sensation Scale (Maisto, Connors, Tucker, and McCollam, 1980), which included items such as drowsy, light headed, and dizzy. Similar estimates, ranging between 0.4 and 0.6, were obtained in an Australian twin study in which subjective response to alcohol was measured across levels of BAC by a single item, namely “how drunk to you feel now” (Heath and Martin, 1991). A more recent laboratory study of the offspring of fathers who completed an alcohol challenge 20 years earlier revealed a significant positive parent-offspring association for subjective feelings of intoxication and body sway, among family history positive individuals (Schuckit, Smith, Kalmijn, and Danko, 2005). Although not providing direct evidence of heritability, this study is consistent with prior reports of the genetic influences on these endophenotypes and provides support for its reliability. A recent experimental twin study has also shown that subjective responses to nicotine in the laboratory are substantially heritable (Ray, Rhee, Stallings, Knopik, and Hutchison, 2007b), yet further work establishing the heritability of certain facets of subjective responses to alcohol are certainly warranted.

**Familial association** refers to the expectation that the endophenotype will be more prevalent among relatives of affected probands, as compared to controls. To that end, there is substantial evidence that subjective responses to alcohol are influenced by family history of alcoholism (e.g., Conrod, Peterson, Pihl, and Mankowski, 1997; Pollock, 1992; Schuckit and Gould, 1988) and a recent study has shown that the number of alcohol dependent relatives was significantly associated with subjective response to alcohol in the laboratory (Schuckit et al., 2005). However, as reviewed by Newlin and Thompson (1990), the broader literature on alcohol challenge studies with sons of alcohol dependent parents and controls is mixed with regard to several behavioral and biological markers.

**Cosegregation**, in turn, is the expectation that the endophenotype will be more prevalent among the affected relatives compared to the unaffected relatives of ill probands. To date, there have been no animal or human studies of cosegregation patterns for alcohol endophenotypes. Finally, **biological and clinical plausibility** refers to the assumption that the endophenotype will bear a conceptual relationship to the disorder of interest. Subjective responses to alcohol are conceptually related to the clinical construct of alcoholism in that individuals who are more sensitive to the rewarding and positive effects of alcohol are thought to crave alcohol more (e.g., consistent with the results in Table 1) and to drink more (Lewis and June, 1990; Wise and Bozarth, 1987), whereas sensitivity to the unpleasant effects of alcohol may deter alcohol use and serve as a protective factor, as discussed below. From a biological standpoint, there is evidence that subjective responses to alcohol are informative regarding neurobiological and genetic factors underlying alcoholism. This evidence will be reviewed in the next sections focusing on pharmacodynamic and pharmacokinetic factors subserving the endophenotype of response to alcohol.

In summary, subjective responses to alcohol appears to meet several of the criteria for evaluating an endophenotype put forth by Tsuang et al. (1993). However, the most consistent evidence comes from studies using the SHAS, which, as discussed above, seems to capture both positive and negative aspects of intoxication, arguably loading most strongly on the negative facets. Therefore, additional work capturing the reinforcing and stimulant
effects of alcohol and carefully examining its utility as an endophenotype for alcoholism is warranted.

Pharmacodynamics

Alcohol intoxication is a complex pharmacological process involving multiple neurotransmitter systems and producing a host of physiological and behavioral effects (Grobin, Matthews, Devaud, and Morrow, 1998; Herz, 1997). As reviewed above, research, primarily from alcohol administration studies, has provided valuable insight into the subjective effects of alcohol ingestion indicating that alcohol’s effects are biphasic in nature (Earleywine, 1994a, 1994b; Earleywine and Martin, 1993; Erblich et al., 2003; Martin et al., 1993). It has been documented that during the ascending limb of intoxication alcohol produces robust stimulatory and other pleasurable subjective effects, whereas during the descending limb alcohol’s effects are predominantly sedative and unpleasant (Earleywine and Martin, 1993; Erblich et al., 2003).

Despite the body of research suggesting that the pharmacological effects of alcohol vary by limb of BAC, human laboratory studies have largely failed to consider limb of intoxication when examining the subjective responses to alcohol. Based on the known pharmacokinetics of alcohol and methods of calculating circulating alcohol (Brick, 2006), the limb of intoxication can often be broadly inferred in most alcohol administration studies via the time elapsed between alcohol intake and assessment, but there is nonetheless substantial ambiguity in the literature. Considering limb of intoxication may also be critically important in evaluating the subjective effects of alcohol and medications, such as naltrexone, that are thought to alter the subjective responses to alcohol. Pharmacokinetics of such medications are also likely to be relevant. This is especially important given that the effects of alcohol clearly vary by limb of the BAC, with well-documented limb-dependent alcohol effects on expectancies (Dunn and Earleywine, 2001), memory (Soderlund, Parker, Schwartz, and Tulving, 2005), cognitive performance (Pihl, Paylan, Gentes-Hawn, and Hoaken, 2003), and the unpleasant subjective effects of alcohol (Evans and Levin, 2004). Specifically, light drinkers are more likely than heavy drinkers to activate negative and sedating alcohol expectancies associated with the descending limb (Dunn and Earleywine, 2001) and report greater dislike of the alcohol during that limb (Evans and Levin, 2004). Impairments in executive cognitive functioning were found to be greater during the descending limb of intoxication (Pihl et al., 2003) and word recognition was found to be impaired only on the ascending limb (Soderlund et al., 2005). Moreover, limb of BAC was proposed as an important feature of the differentiator model (Newlin and Thompson, 1990) of subjective response to alcohol. Together, these findings argue for research that takes into account limb of the BAC when examining the subjective effects of alcohol as well as medications thought to work by altering alcohol’s subjective effects (e.g., reducing its rewarding effects; increasing its unpleasant effects).

Neurobiology and Genetics

There are multiple neurotransmitter systems underlying the subjective effects of alcohol. Given the complexity of the neurobiological and behavioral effects of alcohol we have recently argued for the importance of considering the subjective effects of alcohol a moving
target subserved by multiple neurotransmitter systems (Ray et al., in press). For example, the opioidergic system is thought to mediate some of the rewarding pharmacological effects of alcohol, such as feelings of euphoria and analgesia (Bond et al., 1998; Herz, 1997; Kreek, 1996), and these effects, in turn, are thought to be most prominent during the ascending limb of the BAC.

Given the recognition that the opioidergic system may underlie some of the reinforcing effects of alcohol, there has been recent scientific interest in the genes encoding for endogenous opioid receptors, with a particular focus on the mu-opioid receptor gene (OPRM1). One of the most widely studied polymorphisms of the OPRM1 gene is the +118A/G SNP located in the +118 position in exon 1, which codes for the AsnAsp40 substitution (rs1799971). Molecular studies of this polymorphism initially suggested that the A to G substitution affects receptor activity for endogenous ligand β-endorphin leading to a gain in function, such that the Asp40 variant (i.e., G allele) was thought to bind β-endorphin three times stronger than the Asn40 (i.e., A) allele (Bond et al., 1998). However, a more recent study of the functional significance of this SNP suggested that the Asp allele has deleterious effects on both mRNA and protein yield, leading to a loss of function, rather than a gain (Zhang, Wang, Johnson, Papp, and Sadee, 2005).

Several studies have tested the relationship between the A118G SNP of the OPRM1 gene and substance use disorders, particularly alcoholism and opioid dependence and the results are largely inconsistent. While some investigations have found support for the association between the A118G SNP and alcohol or opioid dependence (Kranzler, Gelernter, O’Malley, Hernandez-Avila, and Kaufman, 1998; Schinka et al., 2002; Tan, Tan, Karupathivan, and Yap, 2003; Town et al., 1999), several studies have failed to find an association (Bergen et al., 1997; Crowley et al., 2003; Franke et al., 2001; Gelernter, Kranzler, and Cubells, 1999; Loh, Fann, Chang, Chang, and Cheng, 2004). However, recent laboratory-based research used an endophenotype-driven approach to studying the effects of the A118G SNP of the OPRM1 gene. Instead of measuring alcohol dependence per se, this study tested the association between this SNP and measures of subjective response to alcohol (Ray and Hutchison, 2004). Results revealed that individuals with at least one copy of the G allele showed greater subjective response to the effects of alcohol measured by subjective intoxication, sedation and stimulation, and changes in mood states, as compared to participants who were homozygous for the A allele. These findings have been recently replicated in an independent sample (Ray and Hutchison, 2007) and this candidate gene has been of interest as a potential mediator of the effects of naltrexone for the treatment of alcoholism (Anton et al., 2008; Oslin et al., 2003). Similar findings were reported in animal models with male rhesus macaques. Here the equivalent OPRM1 polymorphism was associated with increased alcohol response, consumption, and preference (Barr et al., 2007). More broadly, these results provide an example of how endophenotypes may be used to advance our understanding of the pathophysiology of alcoholism. Specifically, subjective responses to alcohol are informative regarding the underlying neuropharmacological effects of alcohol—in suggesting that endogenous opioids may be involved in the rewarding subjective effects of alcohol—which in turn may be used to elucidate candidate genes subserving those effects.

Although the neurotransmitter systems underlying the sedative subjective effects of alcohol have not been clearly characterized, there is some evidence that these effects are mediated by glutamatergic antagonism (Krystal et al., 1998). Likewise, the sedative and anxiolytic effects of alcohol, more prominent during the descending limb, are thought to be mediated by γ-Aminobutric Acid (GABA) neurotransmission (Buck, 1996; Grobin et al., 1998). As discussed above, understanding the substrates
underlying subjective responses to alcohol has the potential to improve gene identification by focusing on a more narrowly defined and biologically relevant phenotype. To that end, a number of genetic association studies have examined candidate genes for level of response to alcohol, as defined by Schuckit and Smith (1996) and Schuckit et al. (1999). Results to date have not been entirely consistent, yet there is some support for the role of variation in the GABA_A6 and serotonin transporter in the subjective response to alcohol in the laboratory (Corbin, Fromme, and Bergenson, 2006; Fromme et al., 2004; Schuckit et al., 1999). In a recent review of the literature on genes contributing to low level of response to alcohol, Schuckit, Smith, and Kamijin (2004) highlighted several candidate gene findings with possible pharmacodynamic effects on level of response to alcohol and alcoholism risk. These findings included genes relating to alterations in the GABAergic system, with a particular focus on GABA_A and its subunits, the serotonin transporter gene, opioid and cannabinoid systems, and genes involved in second messenger systems (e.g., G proteins and protein kinases) (Schuckit et al., 2004). These authors concluded that there is evidence to support the benefits of conducting genetic studies, both linkage and association, on subjective responses to alcohol as an endophenotype for alcoholism. As suggested by Schuckit et al. (2004), the ultimate goal of this line of research is to identify genes that underlie alcohol-related phenotypes, such as level of response to alcohol, and evaluate genetic factors that interact with environmental factors to determine the risk for alcoholism, which in turn can be translated into improved treatment approaches.

**Pharmacokinetics**

In addition to the pharmacodynamic effects reviewed above, another source of genetic influence on the subjective effects of alcohol comes from genetically mediated differences in the metabolism of alcohol as it travels through the body, or in other words, alcohol’s pharmacokinetics. When alcohol is consumed, its metabolic breakdown is a three-step hepatic process in which the alcohol is first oxidized into acetaldehyde by the enzyme alcohol dehydrogenase (ADH) and is then further metabolized into acetate, and other byproducts, by the enzyme aldehyde dehydrogenase (ALDH). The genes responsible for these enzymes exert important influences on the subjective effects of alcohol because they determine the relative levels of these metabolites over the course of alcohol metabolism. Indeed, genes underlying the pharmacokinetics of alcohol are among the best characterized in terms of their influence on subjective responses to alcohol and alcoholism risk.

**Neurobiology and Genetics**

Genetic influences are first evident at the first step in the metabolism of alcohol. As noted above, alcohol is initially broken down in acetaldehyde by ADH. Of the multiple forms of the ADH, the class I isoforms (ADH1A, ADH1B, and ADH1C) play the predominant role in metabolizing alcohol (Edenberg, 2007; Lee et al., 2006). The genes responsible for these enzymes are closely linked on chromosome 4 and the ADH1B and ADH1C genes (coding for the respective isoenzymes) have been determined to have functional polymorphisms. In the case of ADH1B, three polymorphisms of the gene have been identified, of which two (ADH1B-2, ALDH1B-3) are associated with faster enzymatic activity compared to the ADH1B-1 allele, with both resulting in a 70- to 80-fold greater turnover rate. In the case of ADH1C, two variants have been characterized, ADH1C-1 and ADH1C-2, and there is evidence that ADH1C-1 is associated with approximately half the alcohol turnover compared to ADH1C-2. In addition, some Native American groups have been found to carry a third variant of the ADH1C gene (Osier et al., 2002), but that has not been extensively
studied. Most importantly, variation in these genes substantially affects the speed at which an individual metabolizes alcohol into acetaldehyde. For example, the speed of oxidation is estimated to be eight times faster for a man who is homozygous for the ADH1B-2 and ADH1C-1 alleles, as compared to a man who is homozygous for the ADH1B-1 and ADH1C-2 alleles (Lee et al., 2006).

The behavioral and subjective consequences of possession of genetic variants that affect ADH enzymatic activity to increase the presence of acetaldehyde are acutely aversive in nature, including flushing, headache, tachycardia, and nausea. As a result, possession of the ADH1B-2 allele has been demonstrated to reduce the risk of AUDs in populations where the frequency of this allele is high, such as East Asians (Luczak, Glatt, and Wall, 2006; Thomasson et al., 1991; Whitfield, 2002). In addition, even in populations where the allele frequency is lower, a protective effect has been demonstrated for individuals of European and African ancestry (Whitfield, 2002) and individuals of Jewish descent (Luczak et al., 2002; Hasin et al., 2002). Similarly, Edenberg et al. (2006) found that possession of the ADH1B-3 allele reduces the risk of alcoholism in African-Americans, although not in Europeans. Wall, Carr, and Ehlers (2003) found the ADH1B-3 allele had a protective effect among Southwest American Indians. With regard to ADH1C, there is evidence that the faster metabolism of alcohol (i.e., greater accumulation of acetaldehyde), mediated by the possession of the ADH1C-1 allele, has protective effects (Chen et al., 1999; Choi et al., 2005; Osier, Pakstis, and Kidd, 1999). However, these effects are complicated by the fact that the allele is commonly inherited with ADH1B-2 (i.e., these markers are in linkage disequilibrium; LD), making it unclear whether this is an independent effect. In addition, the dynamic and multidimensional nature of these behavioral phenotypes suggest that nonlinear models may be required to capture their complexity (Buscema, 1998).

In addition to the relatively clear effects of genetic effects at the first stage of metabolism, even more robust findings are evident in terms of genetic influences at the second stage of alcohol metabolism, the oxidation of acetaldehyde into acetate. Two ALDH enzymes are responsible for metabolizing acetaldehyde and are encoded by the eponymous genes, ALDH2 and ALDH1A1, on chromosomes 12 and 9, respectively. ALDH2 has two variants, ALDH2–1 and ALDH2–2, and the latter results in an inactive form of the enzyme that cannot metabolize acetaldehyde into acetate. Further, this variant is dominant, so possession of even one ALDH2–2 copy results in almost no hepatic ALDH2 activity (Crabb, Edenberg, Bosron, and Li, 1989). Consequently, ALDH2–2 carriers experience a build-up of acetaldehyde following alcohol consumption, again causing a syndrome of unpleasant effects, including flushing, headache, tachycardia, and nausea. From a functional standpoint, as with the case for polymorphisms affecting acetaldehyde levels via ADH genes, the aversive reaction to alcohol resulting from the ALDH2–2 allele has been robustly demonstrated to result in a substantial protective effect against alcoholism in a number of studies (e.g., Chen et al., 1999; Luczak et al., 2006; Thomasson et al., 1991). In behavioral terms, these individuals experience unpleasant effects of alcohol upon consumption, which makes them less likely to consume alcohol and sharply decreases their risk for developing an AUD. Importantly, the narrowly defined phenotype of unpleasant subjective responses to alcohol (i.e., “flushing” response) has helped scientists further understand the neurobiology of alcohol and its effects, as well as genetic factors underlying this posited protective behavioral phenotype.

In terms of the specific magnitude, a recent large-scale meta-analysis found that ALDH2–2 genotype reduced the risk of alcoholism by 25%–90%. Indeed, in over 4,000 individuals, only 3 cases of alcoholism were identified for ALDH2–2 homozygotes (Luczak et al., 2006). Of note, as with ADH genes, this protective effect generally pertains to
individuals of East Asian ancestry for whom the ALDH2–2 allele is relatively common. Conversely, this polymorphism is rare in individuals of European or African ancestry (Oota, Pakstis, and Bonne-Tamir, 2004). Interestingly, despite its strong putative protective effect, there is evidence the effects of ALDH2 status interact with environmental influences also. Higuchi et al. (1994) report that, from 1979 to 1992, the percentage of Japanese individuals with alcohol dependence who possessed an ALDH2–2 allele increased from 2.5% to 13%, suggesting that the protective effect of the polymorphism was reduced by the greater social acceptability of alcohol use in Japanese culture.

Based on these potent effects via variation in the ALDH2 gene, there is also considerable interest in the ALDH1A1 gene. In contrast to the ALDH2 gene, which is responsible for mitochondrial ALDH activity, ALDH1A1 is responsible for cytosolic ALDH activity (Edenberg, 2007). Variants of the ALDH1A1 gene occur at relatively low frequencies and findings to date have been mixed. For example, Ehlers et al. (2004) found that Southwest California Indians possessing the less functional variant (i.e., resulting in greater acetaldehyde buildup) experienced a protective effect against alcoholism, but Hansell et al. (2005) did not find a protective effect in an Australian community sample. At this point, although variation in ALDH1A1 is promising candidate for exerting similar effects on aversive subjective effects of alcohol and in turn affecting AUD risk, the data are far from definitive.

Taken together, the preceding genetic variants affect the pharmacokinetics of alcohol and further underscore the importance that genetic influences on the subjective effects of alcohol have on risk for AUD. Allelic variation that either results in faster initial accumulation of acetaldehyde (ADH-related genes) or slower breakdown of acetaldehyde (ALDH-related genes) largely determine whether an individual will experience an acutely aversive reaction to alcohol and, in turn, significantly affects the risk for the development of AUD. As such, acetaldehyde accumulation syndrome, including its behavioral effects, is a prototypical intermediate phenotype, intervening between genetic variation and disease liability. Although substantially more remains to be understood about the genes responsible for alcohol’s metabolism, these findings are highly illustrative of an intermediate phenotype approach, and may also provide a model system for potential interventions.

Treatment Applications

There are multiple ways by which alcoholism endophenotypes may be used to improve treatment processes and outcomes. The first approach consists of using endophenotypes as biobehavioral risk markers that can inform secondary prevention efforts through improved identification of individuals at risk. The second, and perhaps most developed approach, consists of using endophenotypes as treatment targets of pharmacological or psychosocial interventions. To that end, it has been postulated that medications that affect the subjective effects of alcohol may hold particular promise for the treatment of alcoholism. For example, two of the four currently FDA-approved pharmacotherapies for alcoholism are thought to work by altering subjective responses to alcohol, namely naltrexone and disulfiram (Antabuse®). Specifically, several studies have shown that naltrexone, an opioid antagonist, alters subjective responses to alcohol by: dampening feelings of alcohol-induced stimulation (Drobes, Anton, Thomas, and Vormin, 2004; Ray and Hutchison, 2007; Swift, Whelihan, Kusnetsov, Buongiorno, and Hsuing, 1994) and alcohol “high” (Volpicelli, Watson, King, Sherman, and O’Brien, 1995), decreasing ratings of liking and enjoyment of the alcohol intoxication (McCaul, Wand, Stauffer, Lee, and Rohde, 2001; Ray and Hutchison, 2007), and increasing self-reported fatigue, tension, and confusion (King, Volpicelli, Frazer, and O’Brien, 1997; Ray et al., in press). Naltrexone’s effects are thought to be mediated through...
the blockade of opioid receptors, which in turn are associated with the reinforcing effects of alcohol upon consumption (Bond et al., 1998; Herz, 1997).

Conversely, disulfiram is a compound that exerts its effects via the same pharmacokinetic pathway associated with the ALDH2–2 allele (reviewed above). In the context of alcohol’s metabolism, disulfiram is an aldehyde dehydrogenase blocker that results in an increase in acetaldehyde after ingested alcohol is oxidized via ADH. This results in a dramatic change in subjective response to alcohol through a set of aversive symptoms caused by acetaldehyde buildup (e.g., nausea, flushing, and tachycardia). These acutely aversive consequences of alcohol consumption are thought to serve as a deterrent to alcohol consumption. Unfortunately, a major limitation of disulfiram’s use in practice is compliance (Suh, Pettinati, Kampman, and O’Brien, 2006); which is also problematic for other addiction pharmacotherapies (e.g., Kranzler, Stephenson, Montejano, Wang, and Gastfriend, 2008). In summary, the biological and behavioral mechanisms of action of both naltrexone and disulfiram exemplify the potential utility of subjective response to alcohol as an endophenotype and its applications to treatment approaches for alcoholism.

An important extension of using endophenotypes, such as subjective responses to alcohol, as pharmacological treatment targets is that information regarding underlying neurobiology and genetics can then be integrated in efforts towards optimizing treatment. Pharmacogenetics represents one important approach towards optimizing treatments for alcoholism on the basis of genetic variance. Specifically, pharmacogenetics is a field of research that seeks to understand individual differences in the metabolism and efficacy of drugs by identifying genetic factors that account for variability in pharmacotherapy effects, both in terms of pharmacodynamics and treatment efficacy (Evans and Johnson, 2001). The field of pharmacogenetics has grown rapidly and has greatly benefited from advancements in molecular genetic tools for identifying gene polymorphisms, developments in bioinformatics and functional genomics, and new findings from the human genome project (Evans and Johnson, 2001). The foremost goal of this line of research is to optimize drug therapy by identifying genetic factors that predict who is more likely to respond to certain pharmacotherapies and who will not respond, therefore matching patients to medications on the basis of genetic factors.

A few studies to date have investigated genetic polymorphisms in the context of pharmacotherapies for alcohol dependence. One such study has found that a polymorphism of the μ-opioid receptor gene (OPRM1) was associated with clinical response to naltrexone among alcohol dependent patients (Osln et al., 2003). The relationship was such that individuals with at least one copy of the variant allele (the A118G SNP of the OPRM1 gene) showed lower relapse rates and longer time to return to heavy drinking when treated with naltrexone (Osln et al., 2003). These findings have been recently replicated in the COMBINE Study (Anton et al., 2008), such that carriers of the G allele receiving Medication Management (MM) showed a significant decrease in heavy drinking days, as compared to homozygotes for the A allele. In addition, 87% of carriers of the G allele had a good clinical outcome to naltrexone + MM, as compared to 55% of homozygotes for the A allele; and the groups did not differ in their response to MM plus placebo (Anton et al., 2008). And overall, naltrexone was superior to placebo in the COMBINE Study when delivered in combination with MM (Anton et al., 2006). However, one recent study did not find support for the moderating role of OPRM1 genotype on clinical response to naltrexone in a sample of male veterans (Gelernter et al., 2007). Moreover, a placebo-controlled laboratory study of naltrexone suggested that individuals who were carriers of the G allele of the OPRM1 gene showed significantly greater naltrexone-induced blunting of alcohol “high,” as compared to individuals who were homozygote for the A allele (Ray and Hutchison,
Subjective Responses to Alcohol Consumption as Endophenotypes

2007). These findings suggest that the differential clinical response to naltrexone, discussed above, may be due to differential blunting of the subjective experience of alcohol reward as a function of genotype, which in turn suggests a biobehavioral mechanism for this important pharmacogenetic relationship. Future studies are certainly needed to probe for this relationship before individualized treatment approaches may be implemented, including consideration of issues such as the differential allele frequencies of this genotype among various ethnic groups (Arias, Feinn, and Kranzler, 2006).

Limitations notwithstanding, the recent literature on the pharmacogenetics of naltrexone provides an example of how endophenotype-driven approaches may be useful tools for advancing the knowledge of alcoholism etiology, neurobiology, and ultimately, treatment efficacy and mechanisms. Translational approaches such as these have the potential to inform clinical practice by identifying individuals who are more likely to benefit from a given pharmacotherapy on the basis of genetic factors. Importantly, a similar framework may be used for optimizing psychosocial interventions that can target certain alcoholism endophenotypes (e.g., craving). In an interesting application of behavioral genetics to optimizing treatment, Bauer et al. (2007) reported that variation within the GABRA2 gene thought to increase the risk for alcoholism (Edenberg et al., 2004), predicted response to the psychosocial interventions tested in Project MATCH. Specifically, the low-risk allele was associated with more robust differences in drinking outcomes in the trial, enhancing the superiority of Twelve-Step Facilitation (TSF) over Cognitive Behavioral Therapy (CBT) and Motivational Enhancement Therapy (MET) (Bauer et al., 2007). In short, these results indicate that the assessment of genetic liability may also be important to studies of the efficacy of psychosocial interventions. More broadly, these results allude to the importance of integrating biological and psychosocial variables to more fully capture the clinical phenomenon of alcoholism.

An Endophenotype-Pharmacogenetic Model

In light of the literature on endophenotypes for alcoholism and their potential to advance etiological and treatment approaches to this disorder, we have developed a conceptual model that ties together alcohol endophenotypes to genetic and pharmacological treatments of alcoholism. To that end, we propose that focusing on alcohol endophenotypes, such as subjective responses to alcohol, and genetic variants subserving those endophenotypes represent important steps towards parsing out the effects of medications on drinking outcomes. More specifically, we posit that alcohol endophenotypes and genetic factors can be used to improve our understanding of pharmacotherapies for alcoholism in several ways (see Figure 1). First, endophenotypes for alcoholism, such as alcohol craving and subjective responses to alcohol, have been shown to predict drinking behavior and the risk for developing alcohol use disorders (e.g., Hines, Ray, Hutchison, and Tabakoff, 2006; Hutchison et al., 2002; Ray, Hutchison, and Bryan, 2006a; Schuckit and Smith, 1996; Tidey et al., 2008). Second, medications found to operate at the level of endophenotypes, such as craving and subjective responses to alcohol (e.g., Monti and MacKillop, 2007; Monti et al., 2001; Ray and Hutchison, 2007), may ultimately be effective in reducing drinking. In a recent example of this approach, a laboratory study found that aripiprazole increased the sedative effects of alcohol and decreased its euphoric and stimulant effects, those effects are thought to capture the mechanisms of action of aripiprazole for alcoholism (Kranzler et al., in press). Third, genetic variants appear to underlie the expression of alcohol endophenotypes such as craving (e.g., Hutchison et al., 2002) and subjective responses to alcohol (e.g., Fromme et al., 2004; Ray and Hutchison, 2004; 2007; Schuckit et al., 2004).
Fourth, genetic variants associated with alcohol endophenotypes may, in turn, be used to predict responses to pharmacotherapies thought to affect those endophenotypes (Ray and Hutchison, 2004, 2007).

In sum, we argue that a theory-driven endophenotype pharmacogenetic approach can be used to enhance the pharmacological treatment of alcoholism. Pharmacotherapies, in turn, may be useful in the context of multiple psychosocial treatment platforms and orientations, including abstinence-based and harm-reduction models. This model is interdisciplinary by nature, as it integrates aspects of behavioral genetics, pharmacology, clinical and experimental psychology. Focusing on theory-driven alcohol endophenotypes and genetic and neurobiological factors underlying these phenotypes may help us elucidate the mechanisms of action of pharmacotherapies, as well as moderators of response. Moreover, this approach has the potential to enhance the translation of basic science to treatment, as it more directly connects endophenotypes and genetic variants to pharmacotherapy outcomes for alcohol dependence. Ultimately, the endophenotype-pharmacogenetic model described herein offers a potentially useful framework for better understanding how endophenotypes and genetic factors concomitantly influence responses to pharmacotherapies for alcoholism. Similar approaches may be useful in optimizing psychosocial interventions by targeting more specific and narrowly defined components of the risk for alcoholism (i.e., prevention efforts) or the clinical syndrome itself (i.e., treatment efforts).

Footnote: Treatment can be briefly and usefully defined as a planned, goal directed, temporally structured change process, of necessary quality, appropriateness and conditions (endogenous and exogenous; micro to macro levels), which is bounded (culture, place, time, etc.) and can be categorized into professional-based, tradition-based, mutual-help based (AA, NA, etc.) and self-help (“natural recovery”) models. There are no unique models or techniques used with substance users, of whatever types and heterogeneities, which are not also used with non-substance users. In the West, with the relatively new ideology of “harm reduction” and the even newer Quality of Life (QOL) treatment-driven model there are now a new set of goals in addition to those derived from/associated with the older tradition of abstinence driven models. Editor’s note.
Future Directions

The literature reviewed herein indicates a number of possibilities for future research with the ultimate goal of translating basic findings into improved treatments for alcoholism. Specifically, as suggested by Insel and Quirion (2005), increased knowledge about the pathophysiology of mental disorders should lead to treatments that are more specific, effective, and accessible. Recent efforts to identify responders to naltrexone as a treatment for alcoholism (e.g., Anton et al., 2008; Ray and Hutchison, 2007) represent initial attempts to develop treatments that are more specific, and as a result, also more efficacious. These efforts are also consistent with the personalized treatment approaches pursued in various fields of medicine. Further characterizing the role of environmental factors (i.e., “E”) and their singular and interactive effects on endophenotypes and disease phenotypes represents a necessary step to more fully understand and treat disorders of complex genetics. Translating some of the promising endophenotypes for alcoholism, such as subjective response to alcohol, into constructs that are measurable outside of the laboratory may help scientists capture the full picture. For example, using ecological momentary assessment (EMA) technology is a promising alternative to capturing subjective response to alcohol, as well as other important environmental and psychological variables, outside of the laboratory setting (e.g., Miranda et al., 2008; Tidey et al., 2008). Likewise, the combination of laboratory, functional imaging (i.e., fMRI), and genetics may be especially helpful in “connecting the dots” by understanding how functional polymorphisms affect brain structure and function, and ultimately behavior (e.g., McClernon, Hutchison, Rose, and Kozink, 2007; Filbey, Ray et al., in press). Finally, the field would benefit from the development of novel intermediate phenotypes, and the refinement of existing phenotypes, to further identify intervening processes/mechanisms by which specific genes exert their influences.

From a pharmacotherapy standpoint, several future directions should be considered. For example, further understanding the pharmacokinetics of medications, including genetically determined differences in drug metabolism, may be helpful in elucidating medication-induced effects on the endophenotypes of interest, such as craving and subjective responses to alcohol. Considering medication pharmacokinetics also raises possibilities for differential pharmacotherapy delivery, such as depo versus oral formulations, and daily versus as needed (i.e., PRN) medication administration. In summary, the study of subjective responses to alcohol has evolved significantly over the past three decades. From the initial characterization of differential response to alcohol by sons of alcohol dependent parents, as compared to controls, to the more recent line of work using subjective response to alcohol as an endophenotype in genetic association studies and pharmacological trials. Nevertheless, considerable work has yet to be done before these advances can be translated into clinical practice. Specifically, further refining the phenotype of subjective response to alcohol and considering both genetic and environmental determinants represent two important steps in the direction of increasing consistency in the literature leading to clinical applications. The endophenotype-driven pharmacogenetic model offers a useful framework for systematically integrating endophenotypes in etiological and treatment models of alcoholism with the ultimate goal of translating these findings into improved prevention and intervention approaches.

Declaration of Interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
THE AUTHORS

**Lara A. Ray, Ph.D.,** is an assistant professor in the Department of Psychology at the University of California Los Angeles (UCLA). She received her doctorate in Clinical Psychology from the University of Colorado at Boulder and completed her clinical internship and fellowship at Brown University. Dr. Ray has received interdisciplinary training in behavioral genetics and her research focuses on the integration of clinical and experimental psychology, pharmacology, and behavioral genetics of addiction.

**James MacKillop, Ph.D.,** is an assistant professor in the Department of Psychology at the University of Georgia. He conducts a program of research studying the determinants of addictive behavior using modern learning theory. This work emphasizes using behavioral economics to study addiction and the integration of genetic variables into behavioral approaches to addiction. Dr. MacKillop received a Ph.D. in clinical psychology from the State University of New York at Binghamton, completing a predoctoral clinical internship at the Brown University Training Consortium. He subsequently completed an NIAAA T32 postdoctoral fellowship in addictions research at Brown’s Center for Alcohol and Addiction Studies and was a faculty member at the Center prior to joining the UGA faculty.

**Peter M. Monti, Ph.D.** Dr. Peter Monti is Donald G. Millar Distinguished Professor of Alcohol and Addiction Studies and Director, Center for Alcohol and Addiction Studies at Brown University. He is also a senior career research scientist for the Department of Veterans Affairs. A recognized leader in understanding the biobehavioral mechanisms that underlie addictive behavior as well as its prevention and treatment, Dr. Monti has published nearly 250 papers, monographs, and chapters primarily focused in the areas of assessment, mechanisms, early intervention, and treatment. His three major books, *Treating Alcohol Dependence: A Coping Skills Training Guide*, *The Tobacco Dependence Treatment Handbook*, and *Adolescents, Alcohol and Substance Abuse*, reflect the breadth of his contributions. He has held research grants from NIAAA, NIDA, and the VA. Dr. Monti is PI of Brown’s NIAAA T32 Postdoctoral Training Program on Treatment and Early Intervention Research, currently in its 25th year. He has trained hundreds of students. Many of these have gone on to become leaders in the field.
Dr. Monti regularly serves on numerous scientific review committees, including those for NIAAA, NIDA, and the VA. He has served as chair of NIAAA’s Portfolio Review Committee, and currently serves on the NIAAA’s Extramural Advisory Board and on the NIH’s National Advisory Council on Alcohol Abuse and Alcoholism. He has sat on numerous editorial boards and is Editor of the Brown University Digest of Addiction Theory and Application (DATA). Dr. Monti has received numerous awards for his research and scholarship. Most recently he was the recipient of the Distinguished Researcher Award from the Research Society on Alcoholism. He is currently immediate past President of the RSA.

Glossary

**Behavioral marker**: a trait or phenotype that is required for the expression of a disorder of interest and that can inform clinical and/or genetic studies.

**Craving**: an inherently subjective experience described as a state of desire or wanting.

**Endophenotypes**: internal phenotypes, not obvious to the untrained eye, which can fill the gap between gene and the behavior or disorder of interest.

**Pharmacodynamics**: the study of biochemical and physiological effects of drugs, such as for the example, drug-receptor interactions.

**Pharmacokinetics**: a field of pharmacology that is concerned with drug absorption, distribution, metabolism and excretion; or in other words, how the body processes drug substances.

**Pharmacogenetics**: the field of research that seeks to understand individual differences in the metabolism and efficacy of drugs by examining genetic variability.

**Phenotype**: any observable trait or characteristic of an individual that is thought to be the result of genes, environment, and their interaction. Research in psychiatric genetics often focuses on diagnostic phenotypes.

**Subjective responses to alcohol**: this construct refers to an individual’s subjective experience of alcohol’s effects, such as feelings of intoxication or “high,” sedation, stimulation, mood alterations, and overall enjoyment of the intoxication effects.

References


